CNAT - Conatus Pharmaceuticals - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

Conatus Pharmaceuticals's activity chart (see below) currently has 20 price targets and 11 ratings on display.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 100% with an average time for these price targets to be met of 968.5 days.

Most recent stock forecast was given by from PIPER SANDLER on 26-Mar-2019. First documented stock forecast 19-Aug-2013.

Best performing analysts who are covering CNAT - Conatus Pharmaceuticals:

Charles Duncan Elemer Piros Ed Arce Stephen Willey Jay Olson Yasmeen Rahimi

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Hold Since 26-Mar-2019

$20

$19.44 (3471.43%)

7 years 5 months 17 days ago
(26-Mar-2019)

1/1 (100%)

$-222 (-91.74%)

422

Hold Since 22-Mar-2019

$8

$7.44 (1328.57%)

$14

7 years 5 months 21 days ago
(22-Mar-2019)

3/3 (100%)

$-248 (-96.88%)

736

Buy Since 06-Dec-2018

$10

$9.44 (1685.71%)

7 years 9 months 6 days ago
(06-Dec-2018)

1/1 (100%)

$-378 (-97.42%)

532

Hold Since 06-Dec-2018

$10

$9.44 (1685.71%)

7 years 9 months 6 days ago
(06-Dec-2018)

1/1 (100%)

$-378 (-97.42%)

532

Hold Since 24-Sep-2015

$5

$4.44 (792.86%)

$9

10 years 11 months 19 days ago
(24-Sep-2015)

2/2 (100%)

$-1163 (-99.57%)

1792

Show more analysts

Please expand the browser size to see the chart

What is CNAT (Conatus Pharmaceuticals) average time for price targets to be met?

On average it took 969 days for the stock forecasts to be reached, with an average price target met ratio of 100%.

Which analyst most recently updated their price target on CNAT (Conatus Pharmaceuticals)?

Which analyst has the most public recommendations on CNAT (Conatus Pharmaceuticals)?

has 0 price targets and 0 ratings on CNAT

Which analyst is the currently most bullish on CNAT (Conatus Pharmaceuticals)?

Yasmeen Rahimi with the highest potential upside of $19.44

Which analyst is the currently most reserved on CNAT (Conatus Pharmaceuticals)?

Charles Duncan with the lowest potential downside of $4.44

To continue looking at which analysts cover the stock please register to the basic or advanced membership

To continue looking at analysts data please register to the advanced membership

What is AnaChart?